The product should become available later this year. This is a once a week dose that can be done at any time of the day. The pen makes it easier for using the injection and has a pre-filled single dose so there’s no need to use a syringe.
Bringing a new tool to the arsenal of medications to treat type 2 diabetes, FDA recently approved the only once-weekly injectable pen for adults with type 2 diabetes—exenatide extended-release for injectable suspension (AstraZeneca, Bydureon Pen).
The 2-mg pre-filled, single-use pen for injection eliminates the need for the patient to transfer the medication between a vial and syringe during the self-injection process, according to AstraZeneca. The pen contains the same formulation and dose as the original Bydureon single-dose tray, providing the same continuous release of exenatide.